全文获取类型
收费全文 | 103298篇 |
免费 | 7835篇 |
国内免费 | 875篇 |
专业分类
耳鼻咽喉 | 1504篇 |
儿科学 | 2202篇 |
妇产科学 | 2102篇 |
基础医学 | 15459篇 |
口腔科学 | 1702篇 |
临床医学 | 9880篇 |
内科学 | 21082篇 |
皮肤病学 | 2962篇 |
神经病学 | 8318篇 |
特种医学 | 4802篇 |
外科学 | 13308篇 |
综合类 | 1756篇 |
现状与发展 | 1篇 |
一般理论 | 51篇 |
预防医学 | 5928篇 |
眼科学 | 3209篇 |
药学 | 8596篇 |
中国医学 | 954篇 |
肿瘤学 | 8192篇 |
出版年
2023年 | 699篇 |
2022年 | 1689篇 |
2021年 | 2896篇 |
2020年 | 1654篇 |
2019年 | 2325篇 |
2018年 | 2789篇 |
2017年 | 2136篇 |
2016年 | 2885篇 |
2015年 | 3634篇 |
2014年 | 4412篇 |
2013年 | 5244篇 |
2012年 | 7644篇 |
2011年 | 7565篇 |
2010年 | 4415篇 |
2009年 | 3728篇 |
2008年 | 5633篇 |
2007年 | 5594篇 |
2006年 | 5304篇 |
2005年 | 5024篇 |
2004年 | 4393篇 |
2003年 | 3953篇 |
2002年 | 3557篇 |
2001年 | 2492篇 |
2000年 | 2370篇 |
1999年 | 2027篇 |
1998年 | 865篇 |
1997年 | 713篇 |
1996年 | 631篇 |
1995年 | 571篇 |
1994年 | 496篇 |
1993年 | 507篇 |
1992年 | 1141篇 |
1991年 | 1148篇 |
1990年 | 1021篇 |
1989年 | 1045篇 |
1988年 | 999篇 |
1987年 | 1001篇 |
1986年 | 860篇 |
1985年 | 813篇 |
1984年 | 626篇 |
1983年 | 511篇 |
1982年 | 359篇 |
1981年 | 323篇 |
1980年 | 311篇 |
1979年 | 471篇 |
1978年 | 363篇 |
1977年 | 267篇 |
1974年 | 273篇 |
1973年 | 294篇 |
1972年 | 258篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
921.
Anthony T C Chan Brigette B Y Ma Y M Dennis Lo S F Leung W H Kwan Edwin P Hui Tony S K Mok Michael Kam Lisa S Chan Samuel K W Chiu K H Yu K Y Cheung Karen Lai Maria Lai Frankie Mo Winnie Yeo Ann King Philip J Johnson Peter M L Teo Benny Zee 《Journal of clinical oncology》2004,22(15):3053-3060
PURPOSE: To assess the efficacy of neoadjuvant paclitaxel and carboplatin (TC) followed by concurrent cisplatin and radiotherapy (RT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and to monitor treatment response with plasma Epstein-Barr virus (EBV) DNA. PATIENTS AND METHODS: Thirty-one patients with International Union Against Cancer stages III and IV undifferentiated NPC had two cycles of paclitaxel (70 mg/m2 on days 1, 8, and 15) and carboplatin (area under the curve 6 mg/mL/min on day 1) on a 3-weekly cycle, followed by 6 to 8 weeks of cisplatin (40 mg/m2 weekly) and RT at 66 Gy in 2-Gy fractions. Plasma EBV DNA was measured serially using the real-time quantitative polymerase chain reaction method. Results All patients completed planned treatment. Response to neoadjuvant TC was as follows: 12 patients (39%) achieved partial response (PR) and 18 achieved (58%) complete response (CR) in regional nodes; five patients (16%) achieved PR and no patients achieved CR in nasopharynx. At 6 weeks after RT, one patient (3%) achieved PR and 30 patients (97%) achieved CR in regional nodes, and 31 patients (100%) achieved CR in nasopharynx; 29 patients (93%) had EBV DNA level of less than 500 copies/mL. Neoadjuvant TC was well tolerated, and the most common acute toxicity of cisplatin plus RT was grade 3 mucositis (55%). At median follow-up of 33.7 months (range, 7 to 39.3 months), six distant and three locoregional failures occurred. Plasma EBV DNA level increased significantly in eight of nine patients who experienced treatment failure but did not increase in those who did not. The 2-year overall and progression-free survival rates were 91.8% and 78.5%, respectively. CONCLUSION This strategy was feasible and resulted in excellent local tumor control. Serial plasma EBV DNA provides a noninvasive method of monitoring response in NPC. 相似文献
922.
Adult medulloblastoma: prognostic factors and patterns of relapse 总被引:10,自引:0,他引:10
Chan AW Tarbell NJ Black PM Louis DN Frosch MP Ancukiewicz M Chapman P Loeffler JS 《Neurosurgery》2000,47(3):623-31; discussion 631-2
OBJECTIVE: To determine the patterns of relapse and the prognostic factors for adult medulloblastomas treated in the magnetic resonance imaging era. METHODS: Between 1986 and 1996, 32 adult patients (age, > or =16 yr) with medulloblastomas confined to the craniospinal axis were treated in our institutions. Twenty cases involved classic histological features and 12 involved the desmoplastic variant. The Chang staging distribution was as follows: T1, 2; T2, 17; T3, 10; T4, 3; M0, 24; M1, 1; M2, 4; M3, 3. Brainstem invasion was present in nine patients. Lesions were midline in 13 cases and lateral in 19. Resection was complete in 17 cases, subtotal in 6, and partial in 5, with biopsy only in 4 cases. All patients received postoperative radiotherapy, with median doses of 36 Gy to the entire craniospinal axis and 55 Gy to the posterior fossa. Twenty-four patients received chemotherapy (20 before radiotherapy, 3 after radiotherapy, and 1 before and after radiotherapy). RESULTS: With a median follow-up period of 5.4 years, 17 patients experienced recurrences. At 5 and 8 years, overall survival rates were 83 and 45% and disease-free survival rates were 57 and 40%, respectively. The 5- and 8-year posterior fossa control rates were 67 and 59%, respectively. Twenty-nine percent of all relapses occurred more than 5 years after treatment. The posterior fossa was the most common site of relapses. In univariate analyses, factors adversely affecting posterior fossa control were less than complete resection (P<0.001), the presence of brainstem invasion (P = 0.02), and the use of chemotherapy (P = 0.03). The overall radiotherapy duration was marginally significant in predicting posterior fossa control, with 5-year posterior fossa control rates of 81 and 49% for durations of less than 48 days and 48 days or more, respectively (P = 0.06). In a multivariate analysis, complete resection was predictive of improved posterior fossa control (P = 0.02) and disease-free survival (P = 0.02) rates. Of the eight low-risk patients who received radiotherapy alone, three experienced recurrences in the bone as the only site of relapse. CONCLUSION: Late relapse is common among adult patients with medulloblastomas, and long-term follow-up monitoring is important. Because of the high risk of systemic failure among the low-risk patients treated with radiotherapy alone, the role of chemotherapy for this group of patients needs to be further investigated. Complete resection, the absence of brainstem invasion, and an overall radiotherapy duration of less than 48 days are important prognostic factors. 相似文献
923.
Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays 总被引:7,自引:0,他引:7
OBJECTIVES: The determination of the percentage of free prostate-specific antigen (%fPSA) enhances the specificity of prostate cancer (CaP) detection. This study was undertaken to assess the performance of %fPSA in differentiating benign prostate disease from CaP and to determine the CaP probability estimates using the AxSYM Free PSA and AxSYM Total PSA assays. METHODS: In this prospective study, 297 men, 50 years old or older, with a total PSA level between 4 and 10 ng/mL and a nonsuspicious digital rectal examination were enrolled at 10 clinical sites. All subjects underwent at least sextant prostate biopsies to establish the diagnosis. fPSA and total PSA (tPSA) levels were determined using the AxSYM Free PSA and AxSYM Total PSA assays. Percent fPSA values were compared with tPSA values to determine the appropriate cutoffs for prostate biopsy and to calculate the CaP probability estimates. RESULTS: The strongest predictor of CaP in a logistic regression model was %fPSA (odds ratio 2.29), which contributed significantly more than age or tPSA to the predictive model. In this study population, a %fPSA cutoff of 26.4% would have detected 96% of subjects with CaP (sensitivity) and would have eliminated 27.4% of unnecessary biopsies (specificity). CaP probability estimates ranged from 9% to 69% and increased as the %fPSA value decreased. Men with a %fPSA level of 10% or lower had a 69% probability of CaP, and men with a %fPSA level of greater than 26% had a 9% probability of CaP. CONCLUSIONS: Percent fPSA values can help differentiate CaP from benign prostate disease and reduce unnecessary biopsies in 27% of men 50 years old or older whose digital rectal examination was normal and whose tPSA level was between 4 and 10 ng/mL. A %fPSA result can assist the physician and patient in determining the probability of CaP and assessing the need for prostate biopsy. 相似文献
924.
The precise role of brachytherapy in treating patients with adenocarcinoma of the prostate remains unclear. Recent literature suggests that the long-term disease-free survival of patients with well-differentiated and localized tumors who receive brachytherapy is comparable to that of patients with similar tumors who are treated with radical prostatectomy or external-beam radiation. Advances in imaging technology, treatment planning software, and delivery apparatus have resulted in a technique that is accurate and reproducible. We explore the development of contemporary brachytherapy and examine the current published data relating to its emergence as a medically successful, cost-effective, and low-morbidity therapeutic modality for patients with stage T(1c), T(2a) prostate cancer. 相似文献
925.
926.
Chan DY Jarrett TW 《Journal of endourology / Endourological Society》2000,14(3):269-72; discussion 272-3
Standard percutaneous nephrolithotomy is highly effective for the removal of renal calculi. However, significant morbidity has been associated with this procedure. Consequently, many urologists inappropriately defer to a less effective procedure to reduce patient morbidity. This practice may increase the total number of procedures needed for treatment and result in a substantial increase in health care costs. Mini-percutaneous nephrolithotomy using a 13F ureteroscopy sheath is described to reduce the morbidity associated with standard percutaneous nephrolithotomy while maintaining its efficiency and effectiveness for stone removal. The indications and technique for mini-percutaneous nephrolithotomy and our results are summarized. 相似文献
927.
The statins as anticancer agents. 总被引:20,自引:0,他引:20
3-Hydroxy-3-methylgutaryl CoA reductase inhibitors, commonly referred to as the statins, have proven therapeutic and preventative effects in cardiovascular diseases. Recently, there are emerging interests in their use as anticancer agents based on preclinical evidence of their antiproliferative, proapoptotic, anti-invasive, and radiosensitizing properties. Inhibition of 3-hydroxy-3-methylgutaryl CoA reductase by the statins interferes with the rate-limiting step of the mevalonate pathway, leading to reduced levels of mevalonate and its downstream products, many of which play important roles in critical cellular functions such as membrane integrity, cell signaling, protein synthesis, and cell cycle progression. Perturbations of these processes in neoplastic cells by the statins may therefore result in control of tumor initiation, growth, and metastasis. The statins have demonstrated growth inhibitory activity in cancer cell lines and preclinical tumor models in animals. Phase I trials of statins in humans have demonstrated myotoxicity as their main dose-limiting toxicity, and Phase II trials in various tumor types are ongoing to evaluate their efficacy. Potential future directions in the development of the statins as anticancer agents include combinations with chemotherapeutic or other molecular-targeted agents, combinations with radiotherapy, maintenance therapy in minimal disease status, and as chemopreventive therapy. 相似文献
928.
929.
930.
Sheila A Prindiville Tim Byers Fred R Hirsch Wilbur A Franklin York E Miller Kieu O Vu Holly J Wolf Anna E Barón Kenneth R Shroyer Chan Zeng Tim C Kennedy Paul A Bunn 《Cancer epidemiology, biomarkers & prevention》2003,12(10):987-993
Individuals with cytological atypia in sputum may be at increased risk for lung cancer. We conducted a longitudinal analysis of the association between lung cancer incidence and cytological atypia in sputum samples collected prospectively from an ongoing cohort of adults at high risk for lung cancer. Cohort members had a smoking history of > or = 30 pack-years and chronic obstructive pulmonary disease documented by pulmonary airflow testing. Sputum samples collected at baseline and periodically thereafter were examined by standard cytological methods. From the cohort of 2,006 people, there were 83 incident lung cancers over 4,469 person-years of observation. At baseline, the association between personal and behavioral characteristics, and sputum cytological atypia was assessed by multiple logistic regression. The association between sputum cytological atypia and incident lung cancer was then assessed by hazard ratios using proportional hazards regression analysis, adjusting for potential confounding factors. Cytological atypia graded as moderate or worse was associated with continuing cigarette smoking (adjusted odds ratio, 2.5; 95% confidence interval, 1.5-4.1), and with lower levels of intake of fruits and vegetables (P for trend = 0.04). Atypia was not associated with several other factors, including the degree of airflow obstruction, the use of vitamin supplements, nonsteroidal anti-inflammatory drugs, or metered-dose steroid inhalers. Incident lung cancer was increased among those with moderate or worse cytological atypia (adjusted hazards ratio, 2.8; 95% confidence interval, 1.4-5.5). This association was not confounded by other risk factors. We conclude that in this high-risk cohort, cytological atypia is associated with continuing smoking and low intake of fruits and vegetables, but that independent of these and other factors, the risk of incident lung cancer is increased among those with moderate or worse grades of cytological atypia in their sputum. 相似文献